<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="704">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>30/09/2005</approvaldate>
  <actrnumber>ACTRN12605000560695</actrnumber>
  <trial_identification>
    <studytitle>A non-blinded randomised controlled study of the efficacy and safety of trimethoprim-sulfamethoxazole vs. norfloxacin for the prevention of spontaneous bacterial peritonitis in cirrhotic patients.</studytitle>
    <scientifictitle>A non-blinded randomised controlled study of the efficacy and safety of trimethoprim-sulfamethoxazole vs. norfloxacin for the prevention of spontaneous bacterial peritonitis in cirrhotic patients.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cirrhosis</healthcondition>
    <healthcondition>Ascites</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Compare the safety and efficacy of trimethoprim-sulfamethoxazole and norfloxacin in preventing spontaneous bacterial peritonitis. Duration is 12 months.</interventions>
    <comparator />
    <control>Active</control>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of spontaneous bacterial peritonitis</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Rate of bacteraemia</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of extraperitoneal bacterial infection</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of hospital admissions</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality rate</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Side effects and tolerabilty to trimethoprim-sulfamethoxazole and norfloxacin</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Resistance rates to trimethoprim-sulfamethoxazole and norfloxacin</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Cirrhotic patient with ascites and either: 1) past history of spontaneous bacterial peritonitis, 2) ascitic protein concentration &lt;15gm/L, 3) bilirubin &gt;42micromol/L.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelopes</concealment>
    <sequence>Computer software performed by pharmacy department</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Paul Gow</name>
      <address>Gastroenterology Department
Austin Health
Studley Rd
Heidelberg VIC 3084</address>
      <phone>+61 3 94965151</phone>
      <fax />
      <email>Paul.Gow@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Steve Lontos</name>
      <address>Gastroenterology Department
Austin Health
Studley Rd
Heidelberg VIC 3084</address>
      <phone>+61 3 94965000</phone>
      <fax />
      <email>Steve.Lontos@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>